Swiss National Bank
IRLA

Swiss National Bank’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Swiss National Bank’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-179
Closed -$222K – 2782
2022
Q1 		$222K Hold
179
– – ﹤0.01% 2671
2021
Q4 		$452K Hold
179
– – ﹤0.01% 2681
2021
Q3 		$3.28M Hold
179
– – ﹤0.01% 1737
2021
Q2 		$1.9M Buy
179
+12
+7% +$101K ﹤0.01% 2138
2021
Q1 		$1.2M Hold
167
– – ﹤0.01% 2279
2020
Q4 		$925K Hold
167
– – ﹤0.01% 2334
2020
Q3 		$1.67M Buy
167
+3
+2% +$27.3K ﹤0.01% 1805
2020
Q2 		$1.52M Buy
+164
New +$1.5M ﹤0.01% 1868

Other funds holding IRLA

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $3.16B AUM 42.38% 1-Year Est. Return

Swiss National Bank's IRLA Position: Q2 2022 in Review

Swiss National Bank sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q2 2022, closing a stake of 179 shares — an estimated $222K sold.

Swiss National Bank first reported a position in IRLA in Q2 2020 and held it in 8 quarters. The position peaked at $3.28M in Q3 2021. 66 funds tracked by Wall St. Rank hold IRLA as of Q2 2022.

  • Swiss National Bank reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Swiss National Bank sold 179 IRulya Therapeutics Inc. Common Stock shares in Q2 2022, an estimated $222K.
  • Swiss National Bank first reported a position in IRulya Therapeutics Inc. Common Stock in Q2 2020 and held it in 8 quarters.
  • Swiss National Bank's IRulya Therapeutics Inc. Common Stock position peaked at $3.28M in Q3 2021.
  • 66 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2022.

Based on Swiss National Bank's 13F filing for Q2 2022, filed 9 Aug 2022.